Delivery Order SPE2DB20D3103-SPE2DB25FQ2K2
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $9,166.56 to AmerisourceBergen Drug Corp for HUMIRA Pen 40 mg/0.8 mL, a pharmaceutical product used in the treatment of autoimmune conditions. This firm fixed-price contract, awarded on September 10, 2025, with an ultimate completion date of September 11, 2025, represents a non-competed delivery order under AmerisourceBergen's existing DLA contract vehicle. The place of performance is listed as the company's corporate office in...
- The Defense Logistics Agency awarded a delivery order valued at $1,394.58 to AmerisourceBergen Drug Corp for HUMIRA (CF) Pen 40 mg/0.4 mls, a pharmaceutical product used to treat inflammatory conditions. The contract was awarded on August 19, 2025, with a completion date of August 20, 2025, and employs firm fixed price pricing with no set-aside designation. The product will be supplied from AmerisourceBergen's facility in Conshohocken, Pennsylvania, where the company maintains its corporate...
- The Defense Logistics Agency awarded a delivery order valued at $3,744.17 to AmerisourceBergen Drug Corp for HUMIRA (CF) Pen 40 mg/0.4 mL, a pharmaceutical product for the treatment of autoimmune conditions. This firm fixed-price delivery order, awarded on August 28, 2025, with an ultimate completion date of August 29, 2025, was competitively awarded without set-aside designation. The product will be delivered to the place of performance in Conshohocken, Pennsylvania, where AmerisourceBergen...
- The Defense Logistics Agency awarded a $17,422.25 delivery order to AmerisourceBergen Drug Corp on September 3, 2025, for the supply of HUMIRA (CF) Pen 40 mg/0.4 mL, a pharmaceutical product used in treating inflammatory conditions. This is a firm fixed-price, non-set-aside contract with an ultimate completion date of September 4, 2025, and performance occurring at AmerisourceBergen's Conshohocken, Pennsylvania location. The delivery order is issued under a larger Indefinite Delivery Contract...
- The Defense Logistics Agency awarded a delivery order valued at $1,458.01 to AmerisourceBergen Drug Corp for HUMIRA (CF) Pen 40 mg/0.4 mls, a brand-name pharmaceutical product used to treat autoimmune conditions. The contract was awarded on August 7, 2025, with an ultimate completion date of August 8, 2025, and utilized firm fixed-price pricing under a non-set-aside competition. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, serves as the prime contractor, with the...
- The Defense Logistics Agency awarded a delivery order valued at $16,204.30 to AmerisourceBergen Drug Corp for the supply of HUMIRA (CF) Pen 40 mg/0.4 mL, a pharmaceutical product used in the treatment of autoimmune conditions. This firm fixed-price delivery order, issued on July 22, 2025, with an ultimate completion date of July 23, 2025, represents a competitively awarded contract with no set-aside designation. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania—the...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 13, 2025, for the supply of HUMIRA (CF) Pen 40 mg/0.4 mls, a specialty pharmaceutical product used in the treatment of autoimmune conditions. This firm fixed-price delivery order, valued at $11,500.66, is scheduled for completion by August 14, 2025, with performance to be executed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. The contract was competitively awarded with no set-aside...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 3, 2025, for the supply of HUMIRA(CF) Pen 40 mg/0.4 mls, a pharmaceutical product used for treating autoimmune conditions. This firm fixed-price delivery order, valued at $1,132.95, represents a non-set-aside competitive award with an ultimate completion date of September 4, 2025. The product will be delivered to the contractor's facility in Conshohocken, Pennsylvania, where AmerisourceBergen...
- The Defense Logistics Agency awarded a delivery order valued at $2,703.97 to AmerisourceBergen Drug Corp for HUMIRA (CF) Pen 40 mg/0.4 mls, a pharmaceutical product used to treat inflammatory conditions. This is a firm fixed price delivery order with no set-aside designation, competitively awarded on August 12, 2025, with an ultimate completion date of August 13, 2025. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office...
- The Defense Logistics Agency awarded a $41,926.99 firm fixed price delivery order to AmerisourceBergen Drug Corp for HUMIRA (CF) Pen 40 mg/0.4 mls pharmaceutical supply. This non-competitive delivery order, awarded on August 13, 2025, with an ultimate completion date of August 14, 2025, represents a child contract under AmerisourceBergen's larger federal pharmaceutical supply vehicle. The product will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania, where...
- SPE2DB20D3103Indefinite Delivery Contract
- SPE2DB20D3103-SPE2DB25FQ2K2Delivery Order
The Defense Logistics Agency awarded a delivery order valued at $7,534.80 to AmerisourceBergen Drug Corp for HUMIRA (CF) Pen 40 mg/0.4 mL, a pharmaceutical product used in the treatment of autoimmune conditions. This firm fixed price, non-set-aside contract was awarded on September 10, 2025, with an ultimate completion date of September 11, 2025. Performance will be executed at AmerisourceBergen's Conshohocken, Pennsylvania facility, where the company maintains its corporate headquarters as a major pharmaceutical distributor and healthcare solutions provider. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (designated SPE2DX), a $999,999,999.00 global pharmaceutical support vehicle running through December 2026. The IDC enables AmerisourceBergen to supply pharmaceutical products and medical supplies to support military healthcare programs, the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems worldwide. The company has demonstrated its capability to meet federal procurement requirements through competitive award processes and maintains an extensive portfolio of pharmaceutical deliveries across multiple therapeutic domains.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $7.5k | 9/10/25 |